Cureveda Launches "Weight-Gut" -- A New-Age, Natural Solution Tackling Bloating, Cravings, and Stubborn Fat Through Gut Health
Mumbai (Maharashtra) [India], June 12: Leading wellness brand Cureveda announced the launch of Weight-Gut, a first-of-its-kind plant-powered weight management formula that targets one of the most overlooked barriers to sustainable weight loss -- poor digestion.
In a landscape dominated by quick-fix fat burners, highly restrictive diets, and hormone-disrupting injections, Cureveda Weight-Gut offers a radically different approach. This scientifically formulated blend combines clinically researched enzymes and potent herbal extracts to improve digestion, boost metabolism, and curb cravings -- all the while reducing bloating and water retention from the very first dose.
"Consumers are waking up to the reality that weight gain is not just about overeating -- it's about how well your body digests and utilizes what you eat," says [Bhavna Anand Sharma], Founder of Cureveda. "Weight-Gut is built around this understanding -- it helps the body do what it's supposed to do: digest, absorb, eliminate -- without forcing it into starvation or hormonal chaos."
The Gut-Fat Connection: A Smarter Strategy for Weight Loss
Research now shows that poor digestion isn't just uncomfortable -- it actively contributes to weight gain. When your digestive system is sluggish or overloaded, food isn't broken down properly. This leads to inefficient nutrient absorption, leaving the body undernourished but still craving more food -- especially sugar and carbs. At the same time, undigested food ferments in the gut, causing bloating, inflammation, and an imbalance in the gut microbiome -- which further slows metabolism and promotes fat storage, particularly around the belly.
Weight-Gut addresses this root cause with its patented Slim-Pur™ Enzyme Blend -- a clinically researched multi-enzyme complex that breaks down proteins, carbs, fats, fiber, and dairy. By supporting better digestion and nutrient assimilation, it reduces bloating, cuts cravings at the source, and helps the body metabolize fat more effectively
Combined with fat-metabolizing botanicals like Garcinia Cambogia, Berberine, and Turmeric, Weight-Gut supports a gradual, natural reduction in fat storage and appetite, while improving overall digestive efficiency -- making diets and workouts work smarter not harder.
Real Results, Real Fast
While most weight-loss supplements rely only on improving metabolism or appetite suppressants, Cureveda Weight-Gut delivers a more sustainable solution:
-Reduces bloating and water weight within hours
-Controls appetite and sugar cravings in days
-Boosts fat metabolism and digestion within weeks
-Promotes visible inch loss around the waist, hips, and thighs over time
In consumer trials, 93% felt lighter within 15 days, and 78% reported an average 2 kg reduction in weight within the first month, along with noticeable improvement in energy and digestion.
A Safe, Non-Invasive Alternative to Weight-Loss Pills
With rising concerns around injectable weight-loss drugs -- from nausea to long-term dependency -- Cureveda Weight-Gut offers a natural, gut-first alternative that works without side effects, prescriptions, or highly restrictive meal plans.
"This is not a detox, not a diet pill, and definitely not a temporary fix. This is a metabolic rebalancer," adds [Bhavna Anand Sharma]. "Weight-Gut trains your body to manage food better, so you lose fat the natural way -- and keep it off."
Availability
Cureveda Weight-Gut is now available online at www.cureveda.com and major e-commerce platforms. It is 100% vegan, gluten-free, and free from artificial additives or synthetic stimulants.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 hours ago
- Time of India
Irritable bowel syndrome with diarrhea: How INSL5 hormone targeting offers new treatment hope
Irritable Bowel Syndrome with diarrhea (Irritable bowel syndrome with diarrhea) is a prevalent digestive disorder affecting millions of people worldwide. Those living with Irritable bowel syndrome with diarrhea often experience frequent, sometimes unpredictable diarrhea, along with abdominal pain, cramping, bloating, and an urgent need to use the restroom. These symptoms can significantly disrupt daily routines, social activities, and mental well-being, making even simple tasks challenging. Conventional treatments for Irritable bowel syndrome with diarrhea typically focus on managing symptoms rather than addressing the underlying cause, leaving many patients frustrated and searching for more effective solutions. However, recent research from the University of Cambridge has shed new light on a gut hormone called Insulin-Like Peptide 5 (INSL5), identifying it as a major contributor in up to 40% of Irritable bowel syndrome with diarrhea cases. This discovery, published in the journal Gut , highlights a clear biological mechanism behind the disorder, paving the way for targeted therapies and more accurate diagnosis. Understanding the role of INSL5 could transform the way Irritable bowel syndrome with diarrhea is treated, offering hope for improved symptom control and a better quality of life for those affected. By focusing on the hormone's influence on gut function, researchers aim to develop therapies that go beyond temporary relief, addressing the root causes of Irritable bowel syndrome with diarrhea and empowering patients to regain control over their digestive health. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Ukraine: Unsold Sofas at Bargain Prices (Prices May Surprise You) Sofas | Search Ads Search Now Undo What is INSL5 and its connection to Irritable bowel syndrome with diarrhea INSL5 is a hormone secreted in the gut that plays a key role in regulating bowel movements. Research has shown that elevated levels of INSL5 are associated with chronic diarrhea, offering a potential explanation for a significant portion of Irritable bowel syndrome with diarrhea cases, especially in patients with bile acid malabsorption. By influencing intestinal motility and fluid secretion, INSL5 contributes directly to the frequent, urgent diarrhea and discomfort experienced by those with Irritable bowel syndrome with diarrhea. Targeting INSL5 presents an opportunity for more precise and effective treatment, focusing on the underlying cause rather than merely managing symptoms. This approach could lead to therapies that improve quality of life, reduce dependency on broad-acting medications, and provide long-term relief for patients who have struggled with conventional symptom-based treatments. Understanding the hormone's role also opens the door to more accurate diagnostics, enabling healthcare providers to identify those most likely to benefit from targeted interventions. How targeting INSL5 could improve diagnosis and treatment Measuring INSL5 levels in patients offers a promising method to differentiate Irritable bowel syndrome with diarrhea from other gastrointestinal conditions, which often present with similar symptoms such as diarrhea, bloating, and abdominal discomfort. Accurate identification can lead to earlier and more targeted interventions, helping patients avoid unnecessary treatments and prolonged symptom management. Existing medications that influence gut hormones, like ondansetron, have already shown some success in relieving diarrhea and improving quality of life, suggesting that hormonal pathways can be effectively modulated. Building on this knowledge, therapies designed specifically to target INSL5 could provide a more precise approach, addressing the underlying cause of Irritable bowel syndrome with diarrhea rather than just mitigating symptoms. Such targeted treatments could transform patient care by reducing flare-ups, enhancing day-to-day comfort, and offering a more personalized strategy for managing this challenging digestive disorder. Research and future directions of INSL5 for Irritable bowel syndrome with diarrhea Ongoing studies are exploring the development of INSL5-inhibiting drugs as well as diagnostic tests that could enable truly personalized management of Irritable bowel syndrome with diarrhea. By gaining a deeper understanding of how this hormone regulates bowel movements, researchers hope to reduce misdiagnoses and limit the need for trial-and-error treatments, which are often frustrating and time-consuming for patients. Targeted therapies focusing on INSL5 could provide faster, more reliable relief, directly addressing the root cause of diarrhea and other symptoms. Over time, this approach has the potential to revolutionize Irritable bowel syndrome with diarrhea care, offering patients a more precise, effective, and sustainable solution that improves daily quality of life and long-term digestive health. Targeting INSL5 has the potential to revolutionize Irritable bowel syndrome with diarrhea management by offering precision treatment for the subset of patients who have long struggled with chronic diarrhea. This breakthrough underscores the critical role gut hormones play in regulating digestive health and opens the door to therapies that address the underlying cause rather than just masking symptoms. By focusing on INSL5, researchers aim to provide more effective, personalized solutions that improve symptom control, enhance quality of life, and reduce the trial-and-error approach often associated with conventional Irritable bowel syndrome with diarrhea treatments. This discovery marks a significant step forward in understanding and managing this challenging condition. Also read| Why every Indian should add vitamin D, B12, and Omega-3 to their diet "Get the latest news updates on Times of India, including reviews of the movie Coolie and War 2 ."
Business Standard
16 hours ago
- Business Standard
Qure.ai Hosts High-Impact Policy Roundtable at Constitution Club of India to Champion AI in Public Health
VMPL New Delhi [India], August 13: a leading Indian deep-tech company and global healthcare AI pioneer, hosted a high-level roundtable on August 6 at the Constitution Club of India. The event brought together Members of Parliament, senior bureaucrats, public health leaders, and international development experts to discuss the role of artificial intelligence in strengthening India's public healthcare systems. The roundtable focused on bringing to light the diverse challenges faced by India's public health system, as voiced by policymakers from across the country. Members of Parliament representing rural and underserved constituencies highlighted gaps in early diagnosis, overburdened health workers, and limited infrastructure--issues that could be effectively addressed through AI-enabled tools. By grounding the conversation in real, on-the-ground realities, the event demonstrated how healthcare AI, when responsibly integrated, could serve as a practical solution to systemic problems. The gathering brought together prominent figures, including Members of Parliament Shri K. Francis George (Kottayam, Kerala), Shri Chatrapati Shahu Maharaj (Kolhapur, Maharashtra), and Shri Darshan Singh Chaudhary (Hoshangabad, Madhya Pradesh), as well as Shri Sudhaker Singh, former Agriculture Minister of Buxar, Bihar. Leaders from the global development sector--such as Mr. Harish Iyer (Gates Foundation), Dr. Jacob Creswell (Stop TB Partnership), Dr. Preet Deep Singh (APNA and Startup India), and Mr. Savio Rodrigues (founder, GoaChronicle)--also contributed to the discussion. Key points raised during the roundtable included the growing burden on frontline health workers, delays in disease detection, and the lack of scalable diagnostic infrastructure, particularly in underserved regions. Several speakers highlighted the urgent need to integrate AI-driven tools into India's healthcare framework, especially for early diagnosis of tuberculosis and non-communicable diseases. Shri Darshan Singh Chaudhary delivered a compelling statement in Hindi, calling AI "the need of the hour" for rural healthcare and urging greater focus on its implementation in resource-constrained areas. Though no formal partnerships were announced, the event generated substantial interest from Members of Parliament and senior officials to explore collaborative models with Attendees conveyed support for future pilots and initiatives, recognising the company's potential to deliver meaningful outcomes across public health programmes. "This roundtable was about action, not announcements," said Prashant Warier, CEO of "The presence of such diverse and respected voices shows that the ecosystem is ready to move from intent to impact. We're focused on real-world use cases, grounded policy support, and long-term commitment. Responsible AI is no longer optional; it has to be part of the foundation." recently named to the TIME100 Most Influential Companies list for 2025, is the only Indian company to feature in this year's edition. With over 4,500 deployments across more than 100 countries, including 1,200 sites in 25 Indian states, its AI solutions are used daily in real-world clinical settings, whether in rural mobile screening vans or high-volume emergency departments. The company's AI models, particularly those designed for chest X-ray interpretation, can detect conditions such as tuberculosis, lung nodules, lung cancer, heart failure and chronic obstructive pulmonary disease (COPD) within seconds. Qure's solutions have cleared findings and regulatory approvals in 92 chest X-ray AI solution has been evaluated by the World Health Organization (WHO) and included in its policy guidance for tuberculosis screening, including in settings without access to a human reader.. In addition to diagnostics, Qure's large language model-powered tools are helping healthcare providers generate structured reports and digitise medical records--critical functions for consistent and responsive care delivery. Qure's partnerships with AstraZeneca, Medtronic India, and Johnson & Johnson Medtech further demonstrate the platform's credibility and interoperability. These collaborations are not limited to product integration--they reflect the trust major Pharma and med-tech players place in Qure's technology and vision. With its latest Series D funding, is focused on deepening its presence in settings where the impact is immediate, from government-run primary health centres to tertiary hospitals. The company's solutions are designed to work within existing clinical workflows, ensuring that innovation complements rather than disrupts care delivery. The roundtable concluded on a strong note of alignment. Legislators, administrators, and public health experts echoed the belief that AI is not a futuristic add-on, but a present-day necessity to build more efficient, equitable, and scalable healthcare systems. The event has laid the groundwork for future collaborations, more policy engagement, and the continued recognition of as a quiet but essential partner in India's health innovation journey. About is a global health tech company that uses deep learning and Artificial Intelligence (AI) to make healthcare more accessible and equitable for patients worldwide. Qure's solutions power the efficient identification and management of Tuberculosis (TB), Lung Cancer and Neurocritical findings to support clinicians and propel developments in the pharmaceutical and medical device industries. The company empowers healthcare by helping to identify conditions fast, prioritize treatment planning and ultimately improve quality of patient life. has presence in over 100 countries, with regional offices in London and New York. The company is also part of the 2025 class of Time100 Most Influential Companies by Time Magazine. (ADVERTORIAL DISCLAIMER: The above press release has been provided by VMPL. ANI will not be responsible in any way for the content of the same)
Business Standard
6 days ago
- Business Standard
Pioneering 'Batman Procedure' Offers New Hope to High-Risk Heart Patients
VMPL New Delhi [India], August 8: Doctors at Rajasthan Hospital Limited (RHL), Jaipur have successfully performed India's first electrosurgical valve-in-valve mitral procedure, informally called the "Batman Procedure", giving a 74-year-old woman from Srinagar a new lease on life. Fatima Bano, who had previously undergone open-heart surgery to replace two valves, was once again facing heart failure. Medical investigations revealed her mitral valve was failing, but her advanced age and health condition made her too high-risk for another conventional open-heart surgery, according to specialists at Srinagar and AIIMS, New Delhi. With her condition worsening and traditional surgery deemed too risky, her family turned to Dr. Ravinder Singh Rao, Chairman, RHL Heart Centre & Head - TAVI Program. Dr. Rao and his team performed the complex procedure using an advanced electrosurgical technique. Using a minimally invasive catheter-based approach, Dr. Rao's team employed precision electrosurgical tools, including a fine electrified wire, to precisely open part of the malfunctioning mitral valve and implant a new one, all without opening the chest. This complex but swift procedure, rarely attempted in such high-risk patients, enabled Fatima to walk within days and return home to her routine life shortly after. "This case proves that even elderly, high-risk patients can receive transformative treatment with the right tools and expertise," said Dr. Rao. This case represents a significant milestone in India's cardiovascular care landscape: the nation's first electrosurgical valve-in-valve intervention for a failed mitral valve in a previously operated patient. The procedure demonstrates the possibility of safely treating complex heart valve disease in elderly, high-risk patients once deemed inoperable.
